40% of people with dementia are still driving.
While hundreds of published reports have made an argument for an association between Alzheimer disease and bacteria and viruses, the suggestion of a viral contribution to Alzheimer disease has not always been well received by the greater research community.
Phase 3 clinical trials for lanabecestat (Eli Lilly and AstraZeneca), an investigational Alzheimer disease treatment, are being discontinued for futility.
The lifetime risks of Alzheimer disease dementia vary considerably by age, gender, and the preclinical or clinical disease state.
There is a reduced risk for dementia for older Chinese adults actively participating in intellectual activities.
Public health strategies for preventing dementia should target socioeconomic gaps to reduce health disparities and protect the disadvantaged.
Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.
These results suggest that antipsychotic exposure has no impact on relative mortality.
The use of certain anticholinergic drugs may increase the risk of future dementia.
Using hearing aids may slow cognitive decline in later life.
These data support the importance of TBI preventative measures and proper management strategies for subsequent dementia.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Should Physicians Treat Family and Friends? Three Experts Weigh In
- Transference in the Age of #MeToo: What Counts as Harassment From a Patient?
- Dialectical Behavior Therapy Effective in Reducing Suicide Attempts, Self-Harm in Adolescents
- Influence of Psychostimulants on BMI and Height in Youth With ADHD
- Medication Adherence Predictors in Patients With Severe Psychiatric Disorders
- Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy
- ADHD Treatments
- Esketamine Nasal Spray: A New Treatment Possibility for Treatment-Resistant Depression
- Pharmacogenetics in Psychiatry: Promising Developments and Potential Pitfalls
- Substance Abuse and Primary Psychosis: A Closer Look
- Functional Restoration for Chronic Pain and Depression in the Elderly: Pharmacotherapy and Beyond
- Efficacy of Long-Acting Injectable Antipsychotics vs Oral Antipsychotics
- Older Age Associated With Worse Major Depressive Disorder Outcomes
- Preoperative Psychiatric Diagnoses Not Associated With Bariatric Surgery Outcomes
- Medical Clearance of Psych Patients in the ED: Consensus Recommendations